Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort

Julien Mazieres, Gerard Zalcman, Lucio Crino, Pamela Biondani, Fabrice Barlesi, Thomas Filleron, Anne-Marie C. Dingemans, Herve Lena, Isabelle Monnet, Sacha I. Rothschild, Federico Cappuzzo, Benjamin Besse, Luc Thiberville, Damien Rouviere, Rafal Dziadziuszko, Egbert F. Smit, Jurgen Wolf, Christian Spirig, Nicolas Pecuchet, Frauke LeendersJohannes M. Heuckmann, Joachim Diebold, Julie D. Milia, Roman K. Thomas, Oliver Gautschi

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)992-+
JournalJournal of Clinical Oncology
Volume33
Issue number9
DOIs
Publication statusPublished - 20 Mar 2015

Cite this

Mazieres, J., Zalcman, G., Crino, L., Biondani, P., Barlesi, F., Filleron, T., Dingemans, A-M. C., Lena, H., Monnet, I., Rothschild, S. I., Cappuzzo, F., Besse, B., Thiberville, L., Rouviere, D., Dziadziuszko, R., Smit, E. F., Wolf, J., Spirig, C., Pecuchet, N., ... Gautschi, O. (2015). Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort. Journal of Clinical Oncology, 33(9), 992-+. https://doi.org/10.1200/JCO.2014.58.3302